Potential synergism between platelet-activating factor and 1-recombinant interferon in promoting luteal maintenance in cyclic ewes
| Autor: | T. J. Parkinson, K. M. Battye, Gareth Evans, L. J. Jenner, Chris O'Neill, G.E. Lamming |
|---|---|
| Rok vydání: | 1993 |
| Předmět: |
Embryology
medicine.medical_specialty Alpha interferon Luteal phase Biology Endocrinology Estrus Pregnancy Internal medicine Luteolysis medicine Animals Platelet Activating Factor Progesterone Interferon alfa Estrous cycle Sheep Obstetrics and Gynecology Drug Synergism Uterine horns Cell Biology Recombinant Proteins Stimulation Chemical medicine.anatomical_structure Reproductive Medicine In utero Corpus Luteum Maintenance Interferon Type I Female Corpus luteum medicine.drug |
| Zdroj: | Reproduction. 97:21-26 |
| ISSN: | 1741-7899 1470-1626 |
| Popis: | In sheep, the presence of an embryo in utero on the 12th to 13th day after oestrus prevents luteolysis. These studies investigated whether platelet-activating factor (PAF) could exert an antiluteolytic function, either alone or in combination with interferon. The intrauterine administration of 250 micrograms PAF per horn per day, administered through indwelling cannulae into the uterus as injections twice a day (n = 12) or by continuous infusion (n = 4) failed to extend luteal function compared with controls (n = 8). When indwelling cannulae were used to administer (i) 125 micrograms PAF per uterine horn, as a bolus infusion twice a day (n = 5), (ii) continuous infusion of 500 micrograms bovine recombinant alpha 1-interferon each day (brIFN, n = 5), (iii) 125 micrograms PAF per horn twice a day, plus 500 micrograms brIFN per day (n = 8), or (iv) vehicle (n = 5), the luteal phase was significantly longer in co-infused (iii) than in control (iv) animals. These findings indicate that pharmacological doses of PAF may act synergistically with interferons to prevent luteolysis. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|